Indonesia Atopic Dermatitis Therapeutics Market Report 2022 to 2030

Indonesia Atopic Dermatitis Therapeutics Market Analysis

$ 3999

The Indonesia Atopic Dermatitis Therapeutics Market was valued at US $74 Mn in 2022, and is predicted to grow at (CAGR) of 8.8% from 2023 to 2030, to US $145 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), growing disposable income and improved healthcare infrastructure. The industry is primarily dominated by players such as Sanofi, Novartis, Abbott, Merck, Roche, GSK, Bristol-Myers Squibb, among others.

ID: IN10IDPH435 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Riddhi Solanki

Buy Now

Indonesia Atopic Dermatitis Therapeutics Market Analysis: Executive Summary

The Indonesia Atopic Dermatitis Therapeutics Market was valued at around US $74 Mn in 2022 and is projected to reach US $145 Mn in 2030, exhibiting a CAGR of 8.8% during the forecast period.

Atopic dermatitis (AD), commonly known as eczema, is a chronic, inflammatory skin condition characterized by redness, itching, and inflammation. It often appears in localized patches on different parts of the body and can be aggravated by factors such as dry skin, stress, and exposure to specific irritants or allergens. Prominent symptoms include intense itching, redness, dryness, and the development of small, fluid-filled blisters that may discharge fluid and form crusts. Emollients are commonly used for skin moisturization, topical corticosteroids for reducing inflammation, and, in severe cases, systemic immunosuppressants. Various pharmaceutical companies manufacture treatments for atopic dermatitis, including Regeneron Pharmaceuticals and Sanofi's Dupixent (Dupilumab), Pfizer's Eucrisa (Crisaborole), and Novartis's Elidel (Pimecrolimus).

Atopic dermatitis affects around 7% of the overall Indonesian population. The market is fueled by significant factors such as the rising prevalence of AD, the growing disposable income of the population, and the evolving healthcare infrastructure in the therapeutics market. However, conditions such as limited access, regulatory hurdles, and competition from traditional medicines limit the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Rising prevalence of AD: The overall prevalence of AD is approximately 7% in the Indonesian population. The increase is attributable to factors such as urbanization, environmental pollution, and genetic susceptibility.

Growing disposable income: The expanding middle class in Indonesia, characterized by rising disposable income, has resulted in increased expenditure on healthcare and pharmaceuticals, including treatments for chronic conditions such as atopic dermatitis.

Improved healthcare infrastructure: The Indonesian government is making significant investments in healthcare infrastructure, extending access to hospitals and pharmacies, particularly in rural regions. This facilitates the broader availability of treatments for atopic dermatitis. Enhancing the local production and distribution of medications for atopic dermatitis can reduce costs and enhance availability, thereby contributing to additional market growth.

Market Restraints

Limited coverage: Unequal distribution of healthcare facilities, especially dermatologists, throughout Indonesia hinders access to accurate diagnosis and treatment, particularly in rural regions. A considerable portion of the population lacks sufficient health insurance, rendering expensive atopic dermatitis therapeutics, such as biologics, financially out of reach for many.

Regulatory hurdles: Rigorous drug approval processes and prolonged registration procedures can postpone the accessibility of recent atopic dermatitis treatments in Indonesia. Reimbursement policies, marked by the insufficient coverage of atopic dermatitis therapeutics under national health insurance programs, additionally curtail access for patients.

Traditional treatment preferences: Relying on traditional remedies and self-medication, though potentially providing certain relief, may impede or postpone the effective use of conventional or advanced therapies. Stigma associated with atopic dermatitis and a lack of awareness regarding its management deter some individuals from seeking appropriate treatment in Indonesia

Healthcare Policies and Regulatory Landscape

The healthcare regulatory landscape in Indonesia is overseen by the National Agency of Drug and Food Control (BPOM). It is responsible for ensuring the safety, quality, and efficacy of pharmaceuticals, food, and cosmetics in Indonesia. The agency plays a crucial role in the approval and regulation of drugs and pharmaceutical products. Companies looking to introduce new drugs to the Indonesian market need to navigate through BPOM's regulatory processes, which include rigorous evaluation and approval procedures to ensure compliance with safety and quality standards.

Obtaining licenses for pharmaceutical products in Indonesia involves a thorough submission and review process with BPOM. Companies must provide comprehensive documentation, including evidence of product safety, efficacy, and quality. Collaboration with local experts, staying informed about regulatory updates, and establishing strong relationships with regulatory authorities are key strategies for new entrants seeking to operate within Indonesia's pharmaceutical market.

Competitive Landscape

Key Players

Sanofi
Novartis
PT Kalbe Pharma
Bayer
Merck Tjahjo Indonesia
Abbott Laboratories
Pharmed
Roche
GlaxoSmithKline
Bristol-Myers Squibb

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Indonesia Atopic Dermatitis Therapeutics Market Segmentation

By Drug Class

Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Biologic Therapy
PDE-4 Inhibitor
Antibiotics
Antihistamines
Emollients

By Route of Administration

Topic
Oral
Injectable

By Severity type

Mild
Moderate
Severe

By Age Group

18 years and below
19 years and above

By Distribution channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Dermatology Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.